Arizona State Retirement System Takes Position in Definium Therapeutics, Inc. $DFTX

Key Points

• Arizona State Retirement System initiated a position in Definium Therapeutics, purchasing 30,411 shares valued at approximately $1.43 million. Institutional investors collectively own 27.91% of the company.
• DFTX shares opened at $36.82, down 8.5%, after the company reported a quarterly loss of $1.44 per share, missing the consensus estimate of a $0.55 loss.
• Analysts remain broadly bullish, with an average “Buy” rating and a $64.88 price target, although company insiders sold 67,119 shares worth about $2.89 million during the last quarter.

Arizona State Retirement System bought a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,411 shares of the company's stock, valued at approximately $1,431,000.

Other institutional investors have also modified their holdings of the company. Avoro Capital Advisors LLC purchased a new position in Definium Therapeutics in the fourth quarter valued at $66,950,000. Wellington Management Group LLP acquired a new stake in Definium Therapeutics in the 2nd quarter valued at $138,755,000. Seven Grand Managers LLC purchased a new stake in Definium Therapeutics in the 4th quarter worth $3,013,000. Seven Fleet Capital Management LP acquired a new position in shares of Definium Therapeutics during the 2nd quarter worth about $6,992,000. Finally, Royce & Associates LP raised its position in shares of Definium Therapeutics by 102.5% during the 4th quarter. Royce & Associates LP now owns 164,041 shares of the company's stock worth $2,197,000 after purchasing an additional 83,017 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company's stock.

Definium Therapeutics Stock Down 8.5%

Shares of NASDAQ:DFTX opened at $36.82 on Wednesday. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $42.77 and a two-hundred day moving average of $30.62. The stock has a market cap of $4.95 billion, a P/E ratio of -10.73 and a beta of 2.23. Definium Therapeutics, Inc. has a 52-week low of $8.77 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, research analysts expect that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DFTX shares. Needham & Company LLC reiterated a "buy" rating and set a $66.00 price objective on shares of Definium Therapeutics in a research note on Monday. Bank of America initiated coverage on Definium Therapeutics in a research report on Tuesday, August 18th. They issued a "buy" rating and a $75.00 target price on the stock. Canaccord Genuity Group set a $78.00 price target on Definium Therapeutics and gave the stock a "buy" rating in a research note on Tuesday. Maxim Group set a $55.00 target price on shares of Definium Therapeutics and gave the company a "buy" rating in a research report on Friday, August 14th. Finally, Oppenheimer reissued an "outperform" rating and issued a $75.00 price target on shares of Definium Therapeutics in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $64.88.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 29,208 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. This represents a 2.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 67,119 shares of company stock valued at $2,887,496. 2.40% of the stock is owned by company insiders.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: DT120 ODT achieved a second Phase 3 success in generalized anxiety disorder (GAD). Definium said the Panorama study met its primary endpoint, with statistically significant improvements in anxiety symptoms. The result strengthens the case for DT120 ODT and reduces clinical-development risk. Definium Reports Second Phase III Success in Anxiety Disorder Program
• Positive Sentiment: The company plans to discuss the results with the FDA and is targeting a regulatory filing in 2027. Successful regulatory engagement could provide the next major catalyst for DFTX. Definium Says Second Phase 3 DT120 Study Meets Goal
• Positive Sentiment: Analysts reinforced the bullish outlook: Robert W. Baird raised its price target to $79 and maintained an “outperform” rating, while HC Wainwright and Needham reiterated “buy” ratings with $70 and $66 targets, respectively. Analyst Ratings
• Neutral Sentiment: DFTX trading was halted temporarily for pending news on September 14, underscoring the significance of the trial announcement and the unusually high volatility surrounding the stock.
• Negative Sentiment: Investors may be locking in gains after DFTX’s sharp recent advance, including a prior jump of as much as 20% on the Phase 3 news. Elevated expectations can also make the stock vulnerable to selling even after favorable results.
• Negative Sentiment: Unusual options activity included purchases of 6,567 put contracts, 68% above typical daily put volume. This may signal hedging or bearish speculation, although it does not confirm a change in the company’s fundamentals.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Want to see what other hedge funds are holding DFTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.